Biopharma R&D 'surged' in 2020, but trial productivity levels a mixed bag: report

A major global pandemic was not enough to stop surging rates of biopharma research and development, but trial productivity still remains below the long-term average.

That is according to a new report out by CRO analytics firm IQVIA, which found that funding for early- and late-stage R&D, as well as deals, jumped last year regardless of the pandemic, while aggregate R&D spend for the top 15 companies “reached a record high.”